Haleon PLC — Director's Dealing 2026

Mar 24, 2026

6-K 1 a9483x.htm DIRECTOR/PDMR SHAREHOLDING Document created using Blueprint(R) - powered by Issuer Services - www.issuerservices.net Copyright 2026 Issuer Services a9483x

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	24
March 2026 - “Director/PDMR Shareholding”

99.1

Haleon plc : Director/PDMR Shareholding

24 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").

This notification sets out the details of the vesting of Haleon share awards over ordinary shares made to a PDMR in March 2023 under the Haleon Performance Share Plan and Deferred Annual Bonus Plan and the subsequent sale of ordinary shares to meet tax liabilities.

On 23 March 2026, Brian McNamara, Chief Executive Officer, received the vesting of awards of Haleon ordinary shares under the Haleon Performance Share Plan and Deferred Annual Bonus Plan. Vesting under both plans included dividends accrued.

The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.

Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The awards are subject to malus and clawback provisions.

| 1 — a) | Details of the issuer or emission allowance market
participant — Name of the entity | Haleon plc | |
| --- | --- | --- | --- |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 2 | Reason for the notification | | |
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment to prior
notifications | Initial Notification | |
| 3 | Details of the person discharging managerial responsibilities /
person closely associated ("PCA") | | |
| a) | PDMR/PCA | PDMR | |
| b) | Name | Brian McNamara | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of Instrument | Share | |
| | Identification code | GB00BMX86B70 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares in respect of the Haleon plc
Performance Share Plan. | |
| c) | Currency, Price(s) and Volume(s) | | |
| | | Price(s) | Volume(s) |
| | | Nil | 1,497,695.24 |
| d) | Aggregated information | | |
| | - Aggregated volume | N/A | |
| | - Price | | |
| e) | Date of the transaction | 23 March 2026 | |
| f) | Place of the transaction | Outside a trading venue | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of Instrument | Share | |
| | Identification code | GB00BMX86B70 | |
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares resulting from Haleon plc
Performance Share Plan vesting to cover tax
liabilities. | |
| c) | Currency, Price(s) and Volume(s) | | |
| | | Price(s) | Volume(s) |
| | | £3.684419 | 704,974.22 |
| d) | Aggregated information | | |
| | - Aggregated volume | N/A | |
| | - Price | | |
| e) | Date of the transaction | 23 March 2026 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of Instrument | Share | |
| | Identification code | GB00BMX86B70 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares in respect of the Haleon plc
Deferred Annual Bonus Plan. | |
| c) | Currency, Price(s) and Volume(s) | | |
| | | Price(s) | Volume(s) |
| | | Nil | 133,733.56 |
| d) | Aggregated information | | |
| | - Aggregated volume | N/A | |
| | - Price | | |
| e) | Date of the transaction | 23 March 2026 | |
| f) | Place of the transaction | Outside a trading venue | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of Instrument | Share | |
| | Identification code | GB00BMX86B70 | |
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares resulting from Haleon plc
Deferred Annual Bonus Plan vesting to cover tax
liabilities. | |
| c) | Currency, Price(s) and Volume(s) | | |
| | | Price(s) | Volume(s) |
| | | £3.684419 | 63,012.31 |
| d) | Aggregated information | | |
| | - Aggregated volume | N/A | |
| | - Price | | |
| e) | Date of the transaction | 23 March 2026 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil , Centrum , Otrivin , Panadol , parodontax , Polident , Sensodyne , Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com .

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| HALEON PLC (Registrant) — /s/
Amanda Mellor | |
| --- | --- |
| Name: | Amanda
Mellor |
| Title: | Company
Secretary |